Abstract
Imaging with 123I-Ioflupane single-photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS] from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I-Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients.
Original language | English |
---|---|
Pages (from-to) | 1175-1182 |
Number of pages | 8 |
Journal | Movement Disorders |
Volume | 19 |
Issue number | 10 |
DOIs | |
Publication status | Published - Oct 2004 |
Keywords
- I-Ioflupane
- Dopamine transporter
- Parkinsonism
- SPECT
ASJC Scopus subject areas
- Clinical Neurology
- Neuroscience(all)